NICA Stock Overview
A nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science applications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Nanologica AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.73 |
| 52 Week High | SEK 11.90 |
| 52 Week Low | SEK 1.68 |
| Beta | 0.39 |
| 11 Month Change | -38.39% |
| 3 Month Change | -64.06% |
| 1 Year Change | -83.17% |
| 33 Year Change | -86.36% |
| 5 Year Change | -85.38% |
| Change since IPO | -92.12% |
Recent News & Updates
Recent updates
Nanologica (STO:NICA) Is Making Moderate Use Of Debt
Oct 10
Is Nanologica AB (publ) (STO:NICA) Trading At A 40% Discount?
Jun 12Does Nanologica (STO:NICA) Have A Healthy Balance Sheet?
Oct 20Nanologica (STO:NICA) Is Making Moderate Use Of Debt
Jun 23Is Nanologica (NGM:NICA) A Risky Investment?
Jan 03Is Nanologica (NGM:NICA) Weighed On By Its Debt Load?
Jun 14Shareholders Are Thrilled That The Nanologica (NGM:NICA) Share Price Increased 115%
Feb 23Shareholder Returns
| NICA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -2.5% | -5.8% | -2.1% |
| 1Y | -83.2% | 14.3% | 10.8% |
Return vs Industry: NICA underperformed the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: NICA underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| NICA volatility | |
|---|---|
| NICA Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: NICA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: NICA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 16 | Andreas Bhagwani | www.nanologica.com |
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science applications worldwide. The company operates through two segments, Drug Development and Chromatography. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA HPLC analytical columns.
Nanologica AB (publ) Fundamentals Summary
| NICA fundamental statistics | |
|---|---|
| Market cap | SEK 75.99m |
| Earnings (TTM) | -SEK 88.43m |
| Revenue (TTM) | SEK 8.76m |
8.7x
P/S Ratio-0.9x
P/E RatioIs NICA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NICA income statement (TTM) | |
|---|---|
| Revenue | SEK 8.76m |
| Cost of Revenue | SEK 7.44m |
| Gross Profit | SEK 1.33m |
| Other Expenses | SEK 89.76m |
| Earnings | -SEK 88.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 07, 2025
| Earnings per share (EPS) | -2.00 |
| Gross Margin | 15.15% |
| Net Profit Margin | -1,009.07% |
| Debt/Equity Ratio | -0.3% |
How did NICA perform over the long term?
See historical performance and comparison